Treating Tumors with TTFields and an Aurora Kinase Inhibitor
First Claim
1. A method of reducing viability of cancer cells, the method comprising:
- administering an Aurora kinase inhibitor to the cancer cells; and
applying an alternating electric field to the cancer cells, the alternating electric field having a frequency between 100 and 300 kHz.
6 Assignments
0 Petitions
Accused Products
Abstract
The viability of cancer cells can be reduced by administering an Aurora kinase inhibitor (e.g., MLN8237 or another Aurora A kinase inhibitor, AZD1152 or another Aurora B kinase inhibitor) to the cancer cells, and applying an alternating electric field with a frequency between 100 and 300 kHz (e.g., 200 kHz) to the cancer cells. Furthermore, cancer (e.g., glioblastoma) in a subject may be treated by administering an Aurora kinase inhibitor to the subject, and applying an alternating electric field with frequency between 100 and 300 kHz (e.g., 200 kHz) to a target region of the subject (e.g., the brain).
-
Citations
27 Claims
-
1. A method of reducing viability of cancer cells, the method comprising:
-
administering an Aurora kinase inhibitor to the cancer cells; and applying an alternating electric field to the cancer cells, the alternating electric field having a frequency between 100 and 300 kHz. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)
-
-
14. A method of treating cancer in a subject, the method comprising:
-
administering a therapeutically effective dose of an Aurora kinase inhibitor to the subject; and applying an alternating electric field to a target region of the subject, the alternating electric field having a frequency between 100 and 300 kHz. - View Dependent Claims (15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)
-
Specification